AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer

AstraZeneca and Merck’s Lynparza is looking to become the first in its class of PARP inhibitors to break into the pancreatic cancer market. And a majority of FDA advisors thinks it should be—if only a small one.